House Representatives Worried OTC Plan B May Increase Adolescent STD Risk
This article was originally published in The Tan Sheet
Executive Summary
Political pressure could affect the pending FDA decision on Barr Labs' application for over-the-counter status for emergency contraceptive Plan B (levonorgestrel)
You may also be interested in...
Plan B May Prevent Vote On Crawford FDA Commissioner Confirmation
Senate Health Committee Democrats will put a hold on Lester Crawford's nomination to permanent FDA Commissioner pending an agency decision on the Rx-to-OTC switch application for Barr Labs' Plan B emergency contraceptive
Plan B May Prevent Vote On Crawford FDA Commissioner Confirmation
Senate Health Committee Democrats will put a hold on Lester Crawford's nomination to permanent FDA Commissioner pending an agency decision on the Rx-to-OTC switch application for Barr Labs' Plan B emergency contraceptive
Plan B May Prevent Vote On Crawford FDA Commissioner Confirmation
Senate Health Committee Democrats will put a hold on Lester Crawford's nomination to permanent FDA Commissioner pending an agency decision on the Rx-to-OTC switch application for Barr Labs' Plan B emergency contraceptive